Last reviewed · How we verify
PACx14
PACx14 is a chemotherapy regimen combining paclitaxel, doxorubicin, and cyclophosphamide administered in a dose-dense schedule for cancer treatment.
PACx14 is a chemotherapy regimen combining paclitaxel, doxorubicin, and cyclophosphamide administered in a dose-dense schedule for cancer treatment. Used for Breast cancer (likely early-stage or metastatic, under investigation in SWOG trials).
At a glance
| Generic name | PACx14 |
|---|---|
| Also known as | Lansoprazole: Prevacid |
| Sponsor | SWOG Cancer Research Network |
| Drug class | Multi-agent chemotherapy regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PACx14 represents a multi-agent chemotherapy combination where paclitaxel (a microtubule stabilizer), doxorubicin (a topoisomerase II inhibitor and intercalating agent), and cyclophosphamide (an alkylating agent) work synergistically to induce cancer cell death. The 'x14' designation likely refers to the number of treatment cycles or a specific dosing schedule. This regimen is designed to maximize cytotoxic effect while being administered in a dose-dense manner to improve efficacy.
Approved indications
- Breast cancer (likely early-stage or metastatic, under investigation in SWOG trials)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PACx14 CI brief — competitive landscape report
- PACx14 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI